Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Immunotherapy with 3BNC117 elicits host immune responses against HIV-1

May 31, 2016

Theratechnologies presents preliminary primary endpoint results from phase III ibalizumab trial

May 25, 2016

Wisconsin Alumni Research Foundation reports HIV protease inhibitors

May 23, 2016

NIH-funded phase IIb/III trial to evaluate HIV vaccine regimen in South Africa

May 20, 2016

GeoVax Labs plans new trial of HIV vaccine GOVX-B11

May 19, 2016

Viriom raises funding for the development of elpivirine

May 13, 2016

Gilead's MAA for Odefsey single tablet regimen receives positive opinion for the treatment of HIV

May 2, 2016

Gilead Sciences's Descovy approved in E.U.

April 26, 2016

CytoDyn reports complete viral load suppression in ongoing PRO-140 monotherapy extension study

April 20, 2016

GeoVax receives SBIR grant for clade B HIV vaccine

April 15, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...